LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The LMO2 oncogene is frequently deregulated in human T-cell leukemias.
• Gene therapy has also been linked to T-cell leukemias due to oncogene dysregulation.

Purpose of the Study:

• To investigate the role of LMO2 in T-cell acute lymphoblastic leukemia (T-ALL) development.
• To explore the gene expression patterns associated with LMO2-induced T-ALL.
• To establish a mouse model for studying T-ALL pathogenesis.

Main Methods:

• Generation of transgenic mice with enforced Lmo2 expression in T-cells using the CD2 promoter/enhancer.
• Analysis of gene expression patterns in developing T-ALL.
• Conditional inactivation of the Hhex gene in transgenic mice.

Main Results:

• Transgenic mice developed T-ALL with two distinct gene expression patterns, including activation of Lyl1, Hhex, and Mycn, or Notch1 target genes.
• These gene expression clusters mirrored those found in human Early T-cell Precursor ALL (ETP-ALL).
• HHEX was identified as a direct transcriptional target of LMO2, and its inactivation significantly reduced T-ALL development.

Conclusions:

• HHEX is a critical mediator of LMO2's oncogenic function in T-ALL.
• The CD2-Lmo2 transgenic mouse model provides insights into concordant oncogene expression.
• This model is valuable for studying the treatment-resistant ETP-ALL subtype.